BEATRIZ
ARRIZABALAGA AMUCHASTEGUI
![Foto de BEATRIZ](/img/nophoto.png)
![Foto de Hospital Clinico Universitario de Valencia](/img/noimage_org.png)
Hospital Clinico Universitario de Valencia
Valencia, EspañaHospital Clinico Universitario de Valencia -ko ikertzaileekin lankidetzan egindako argitalpenak (8)
2020
-
Optimised molecular genetic diagnostics of Fanconi anaemia by whole exome sequencing and functional studies
Journal of Medical Genetics, Vol. 57, Núm. 4, pp. 258-268
-
miR-146a rs2431697 identifies myeloproliferative neoplasm patients with higher secondary myelofibrosis progression risk
Leukemia, Vol. 34, Núm. 10, pp. 2648-2659
2017
-
Clinical and biological significance of isolated Y chromosome loss in myelodysplastic syndromes and chronic myelomonocytic leukemia. A report from the Spanish MDS Group
Leukemia Research, Vol. 63, pp. 85-89
-
Enumerating bone marrow blasts from nonerythroid cellularity improves outcome prediction in myelodysplastic syndromes and permits a better definition of the intermediate risk category of the Revised International Prognostic Scoring System (IPSS-R)
American Journal of Hematology, Vol. 92, Núm. 7, pp. 614-621
-
Oxidative imbalance in low/intermediate-1-risk myelodysplastic syndrome patients: The influence of iron overload
Clinical Biochemistry, Vol. 50, Núm. 16-17, pp. 911-917
2016
-
Considering bone marrow blasts from nonerythroid cellularity improves the prognostic evaluation of myelodysplastic syndromes
Journal of Clinical Oncology, Vol. 34, Núm. 27, pp. 3284-3292
2014
-
Multivariate time-dependent comparison of the impact of lenalidomide in lower-risk myelodysplastic syndromes with chromosome 5q deletion
British Journal of Haematology, Vol. 166, Núm. 2, pp. 189-201
-
Transfusion dependence development and disease evolution in patients with MDS and del(5q) and without transfusion needs at diagnosis
Leukemia Research, Vol. 38, Núm. 3, pp. 304-309